<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666663</url>
  </required_header>
  <id_info>
    <org_study_id>18-25736_SPG_2018.09</org_study_id>
    <nct_id>NCT03666663</nct_id>
  </id_info>
  <brief_title>Sphenopalatine Ganglion Blocks RCT</brief_title>
  <acronym>SPGblock</acronym>
  <official_title>UCSF Sphenopalatine Ganglion Block Study- a Randomized Double Blind Placebo Controlled Trial to Compare Nasal Anesthetics for Migraine Prevention in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT of Sphenopalatine Ganglion (SPG) Blocks using anesthetics vs. placebo for migraine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic Migraine is a brain disorder with high prevalence. It is the 7th leading cause of
      disability worldwide according the WHO.

      SPG block is a treatment for migraine that has been used for two decades. It can be done by
      needle injection of anesthetic to the region of the SPG. However, there are now multiple
      catheter devices that can be used to non-invasively administer anesthetic topically through
      the nasal cavity to the region of the SPG where the anesthetic is then absorbed through thin
      membranes covering the SPG.

      Various anesthetic agents have been studied however currently, to our knowledge, there is no
      head to head comparison of the various anesthetics used. Studies of SPG blocks in the setting
      of chronic migraine are few as compared to the use of SPG as acute treatment for migraine.

      With the use of an RCT, we aim to determine the overall efficacy of SPG blocks used at longer
      intervals than have been studied in the past as compared to placebo, as well as to examine
      the relative efficacy of the anesthetics used most commonly and studied for SPG blocks.

      We will be using an FDA cleared device, the Sphenocath which was developed and registered
      with the FDA for this specific population and purpose. The study intervention is the standard
      practice in the UCSF Headache Center to perform SPG blocks for our patients with chronic
      migraine. The frequency we use in clinical practice and that we plan to study is less often
      than in previous studies of this intervention in this population.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized placebo controlled study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in headache days</measure>
    <time_frame>8 months</time_frame>
    <description>Reduction in headache days from baseline to month 8 of treatment</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with lidocaine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive SPG blocks with ropivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive SPG blocks with placebo (saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Nasal application using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Ropivacaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Saline using the Sphenocath device- cleared by FDA</description>
    <arm_group_label>Placebo (saline)</arm_group_label>
    <other_name>Placebo Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 years or more at time of consent

          2. Current patients in the UCSF Headache Center eligible to receive SPG blocks for
             migraine and would otherwise receive treatment clinically

          3. Ability to provide consent for the research study

        Exclusion Criteria

          1. Pregnant or breast feeding within 4 weeks of enrollment

          2. Inability to communicate with the study team

          3. Patients who cannot read and understand English

          4. Deemed unsuitable for enrollment in study by the investigator

          5. Allergy to local anesthetics or saline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nina Riggins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSF Headache Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nina Riggins, MD</last_name>
    <phone>415-353-8393</phone>
    <email>nina.riggins@ucsf.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCSF Headache Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Riggins, MD</last_name>
      <phone>415-353-8393</phone>
      <email>nina.riggins@ucsf.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goadsby PJ, Zagami AS, Lambert GA. Neural processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache. 1991 Jun;31(6):365-71.</citation>
    <PMID>1889975</PMID>
  </results_reference>
  <results_reference>
    <citation>Piagkou M, Demesticha T, Troupis T, Vlasis K, Skandalakis P, Makri A, Mazarakis A, Lappas D, Piagkos G, Johnson EO. The pterygopalatine ganglion and its role in various pain syndromes: from anatomy to clinical practice. Pain Pract. 2012 Jun;12(5):399-412. doi: 10.1111/j.1533-2500.2011.00507.x. Epub 2011 Sep 29. Review. Erratum in: Pain Pract. 2012 Nov;12(8):673.</citation>
    <PMID>21956040</PMID>
  </results_reference>
  <results_reference>
    <citation>Robbins MS, Robertson CE, Kaplan E, Ailani J, Charleston L 4th, Kuruvilla D, Blumenfeld A, Berliner R, Rosen NL, Duarte R, Vidwan J, Halker RB, Gill N, Ashkenazi A. The Sphenopalatine Ganglion: Anatomy, Pathophysiology, and Therapeutic Targeting in Headache. Headache. 2016 Feb;56(2):240-58. doi: 10.1111/head.12729. Epub 2015 Nov 30. Review.</citation>
    <PMID>26615983</PMID>
  </results_reference>
  <results_reference>
    <citation>Mehta D, Leary MC, Yacoub HA, El-Hunjul M, Kincaid H, Koss V, Wachter K, Malizia D, Glassman B, Castaldo JE. The Effect of Regional Anesthetic Sphenopalatine Ganglion Block on Self-Reported Pain in Patients With Status Migrainosus. Headache. 2019 Jan;59(1):69-76. doi: 10.1111/head.13390. Epub 2018 Jul 25.</citation>
    <PMID>30043973</PMID>
  </results_reference>
  <results_reference>
    <citation>Binfalah M, Alghawi E, Shosha E, Alhilly A, Bakhiet M. Sphenopalatine Ganglion Block for the Treatment of Acute Migraine Headache. Pain Res Treat. 2018 May 7;2018:2516953. doi: 10.1155/2018/2516953. eCollection 2018.</citation>
    <PMID>29862074</PMID>
  </results_reference>
  <results_reference>
    <citation>Mojica J, Mo B, Ng A. Sphenopalatine Ganglion Block in the Management of Chronic Headaches. Curr Pain Headache Rep. 2017 Jun;21(6):27. doi: 10.1007/s11916-017-0626-8. Review. Erratum in: Curr Pain Headache Rep. 2017 Nov 20;21(12 ):53. Mojica, Jeffery [corrected to Mojica, Jeffrey].</citation>
    <PMID>28432602</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 8, 2018</study_first_submitted>
  <study_first_submitted_qc>September 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Nina Riggins, MD</investigator_full_name>
    <investigator_title>Assistant Clinical Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

